Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

SimBioSys secures $15 million in Series A funding for computational oncology software

By Brian Buntz | October 26, 2021

SimbiosysThe developer of a cloud-based application for oncology care and research, SimBioSys, has raised $15 million in Series A funding. Genoa Ventures and Northpond Ventures led the funding round, which also involved AV8 Ventures, Heritage Medical Group, and Mayo Clinic.

SimBioSys also announced that existing investors and its founders participated in the financing, raising a total of $21 million.

The company plans on using the funds for the development and commercialization of its TumorScope software platform. In particular, the company plans on using the funding to digitize and model treatment options for a number of solid tumors, including in breast cancer.

TumorScope is a cloud-based application that virtualizes cancer in three dimensions. The company reports that it can accurately simulate how a patient’s tumor will respond to a variety of therapies following diagnosis. “Simulating a response before prescribing treatment is a significant stride in personalized treatment planning,” said a company spokesperson.

The company was founded in 2018 by researchers at the University of Illinois Urbana-Champaign to explore the intersection between AI and biophysical simulations in oncology.

The company’s platform integrates AI with biophysical simulations to model a range of variables such as drug delivery, metabolism and spatial heterogeneity.

SimBioSys said the platform can assist with drug development across pre-clinical and clinical trials.

SimBioSys is currently collaborating with 20 cancer institutions to clinically validate its software.

One study published in the Journal of Clinical Oncology found that its software was 92% accurate in predicting the response to neoadjuvant chemotherapy in early breast cancer.

Co-founder and CEO of SimBioSys Tushar Pandey was researching strategies to reduce healthcare costs by helping providers understand and analyze the true cost of care. After his mother received a cancer diagnosis, he met Dr. Joseph Peterson and Dr. John Cole. The three would join together to found SimBioSys.


Filed Under: Drug Discovery, Oncology
Tagged With: AI, Genoa Ventures, Northpond Ventures, oncology, SimBioSys
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio
Axcella
Axcella touts positive results from Phase 2a long COVID study
artificial intelligence
Defining complexity: A framework to identify complex clinical trials and set them up for success

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50